Complications of bacillus Calmette-Guérin immunotherapy
- PMID: 1636240
Complications of bacillus Calmette-Guérin immunotherapy
Abstract
Knowing when to give and when to withhold BCG will prevent most complications, but even when all precautions are taken, some complications will occur. The initial step in the treatment of infectious complications is the use of isoniazid. Routine prophylactic isoniazid should not be given, as animal studies have confirmed that immune stimulation, and presumably antitumor activity, can be inhibited by isoniazid prophylaxis. However, when cystitis persists more than 2 days or is so severe that it does not respond to symptomatic treatment, isoniazid 300 mg daily is used to control the symptoms, prevent progressive infection, and avoid the overgrowth of BCG, which can result in excessive organisms and suppression of the immune response. If symptoms progress despite isoniazid treatment or do not begin to abate within 1 to 2 weeks, rifampicin 600 mg daily is added. Rifampicin is given from the beginning in patients with potentially severe extravesical BCG infection such as pneumonitis, hepatitis, or nephritis. In patients with symptoms such as fever, malaise, or bladder irritation that respond within a few days, it generally is necessary to continue antitubercular antibiotics for only 2 weeks. Those with extravesical infection and those who do not respond promptly to treatment are treated for 3 months, and those with severe or deep-seated infection are treated for 6 months. The current recommendation for the treatment of sepsis after BCG administration, based on limited clinical experience and controlled animal experimentation, is to use isoniazid and rifampicin plus prednisolone 40 mg daily.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.Arch Esp Urol. 1991 Oct;44(8):1025-8. Arch Esp Urol. 1991. PMID: 1796850 Clinical Trial.
-
Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer.Compr Ther. 1994;20(12):695-701. Compr Ther. 1994. PMID: 7882653 Review. No abstract available.
-
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.J Urol. 2000 Apr;163(4):1124-9. J Urol. 2000. PMID: 10737480 Clinical Trial.
-
Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer.Prog Clin Biol Res. 1989;310:325-34. Prog Clin Biol Res. 1989. PMID: 2672020
-
Intravesical therapy for superficial bladder cancer.Semin Urol Oncol. 2000 Nov;18(4):280-8. Semin Urol Oncol. 2000. PMID: 11101091 Review.
Cited by
-
Disseminated Mycobacterium bovis Infection Complicating Intravesical BCG Instillation for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder.Clin Med Insights Case Rep. 2016 Aug 16;9:71-3. doi: 10.4137/CCRep.S39904. eCollection 2016. Clin Med Insights Case Rep. 2016. PMID: 27559301 Free PMC article.
-
Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment.J Urol. 2013 Apr;189(4):1268-74. doi: 10.1016/j.juro.2012.10.070. Epub 2012 Oct 30. J Urol. 2013. PMID: 23123375 Free PMC article. Clinical Trial.
-
Theories behind Bacillus Calmette-Guérin failure in high-risk non-muscle-invasive bladder cancer and update on current management.Cancer Pathog Ther. 2023 Nov 29;2(2):74-80. doi: 10.1016/j.cpt.2023.11.004. eCollection 2024 Apr. Cancer Pathog Ther. 2023. PMID: 38601486 Free PMC article. Review.
-
Clinical Aspects of Adult Tuberculosis.Cold Spring Harb Perspect Med. 2015 Feb 6;6(1):a017848. doi: 10.1101/cshperspect.a017848. Cold Spring Harb Perspect Med. 2015. PMID: 25659379 Free PMC article. Review.
-
The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery.Life (Basel). 2020 Oct 5;10(10):231. doi: 10.3390/life10100231. Life (Basel). 2020. PMID: 33027905 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical